Picomolar dichotomous activity of gnidimacrin against hiv-1

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Huang, Li ^a   Ho, Phong ^a   Yu, Jie ^a   Zhu, Lei ^a   Lee, Kuo Hsiung ^b,c   Chen, Chin Ho ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DITERPENOID; ENZASTAURIN; GNIDIMACRIN; PROSTRATIN; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C BETA; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DITERPENE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL KILLING; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 R5; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR DOWN REGULATION; VIRUS ACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; MICROBIOLOGICAL EXAMINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; CELL LINE; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 80055048496     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026677     Document Type: Article

References (33)

1. Pereira CF, Paridaen JT, (2004) Anti-HIV drug development - an overview. Curr Pharm Des 10: 4005-4037.
2. Dau B, Holodniy M, (2009) Novel targets for antiretroviral therapy: clinical progress to date. Drugs 69: 31-50.
3. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
5. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
6. Persaud D, Zhou Y, Siliciano JM, Siliciano RF, (2003) Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 77: 1659-1665.
7. Borris RP, Blaskó G, Cordell GA, (1988) Ethnopharmacologic and phytochemical studies of the Thymelaeaceae. J Ethnopharmacol 24: 41-91.
8. Zhang L, Luo RH, Wang F, Jiang MY, Dong ZJ, et al. (2010) Highly functionalized daphnane diterpenoids from Trigonostemon thyrsoideum. Org Lett 12: 152-155.
9. Zhang L, Luo RH, Wang F, Dong ZJ, Yang LM, et al. (2010) Daphnane diterpenoids isolated from Trigonostemon thyrsoideum as HIV-1 antivirals. Phytochem 71: 1879-1883.
10. Wender PA, Koehler KF, Sharkey NA, Dell'Aquila ML, Blumberg PM, (1986) Analysis of the phorbol ester pharmacophore on protein kinase C as a guide to the rational design of new classes of analogs. Proc Natl Acad Sci USA 83: 4214-4218.
11. Yoshida M, Feng W, Saijo N, Ikekawa T, (1996) Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer 66: 68-73.
12. Yoshida M, Yokokura H, Hidaka H, Ikekawa T, Saijo N, (1998) Mechanism of antitumor action of PKC activator, gnidimacrin. Int J Cancer 77: 243-250.
13. Yoshida M, Heike Y, Ohno S, Ikekawa T, Wakasugi H, (2003) Involvement of PKC beta II in anti-proliferating action of a new antitumor compound gnidimacrin. Int J Cancer 105: 601-606.
14. Nelson TJ, Alkon DL, (2009) Neuroprotective versus tumorigenic protein kinase C activators. Trends Biochem Sci 34: 136-45.
15. Gustafson KR, Cardellina JH II, McMahon JB, Gulakowski RJ, Ishitoya J, et al. (1992) A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem 35: 1978-1986.
16. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, et al. (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98: 3006-3015.
17. Biancotto A, Grivel JC, Gondois-Rey F, Bettendroffer L, Vigne R, et al. (2004) Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol 78: 10507-10515.
18. Bocklandt S, Blumberg PM, Hamer DH, (2003) Activation of latent HIV-1 expression by the potent anti-tumor promoter 12-deoxyphorbol 13-phenylacetate. Antiviral Res 59: 89-98.
19. Fujiwara M, Ijichi K, Tokuhisa K, Katsuura K, Shigeta S, et al. (1996) Mechanism of selective inhibition of human immunodeficiency virus by ingenol triacetate. Antimicrob Agents Chemother 40: 271-273.
20. Warrilow D, Gardner J, Darnell GA, Suhrbier A, Harrich D, (2006) HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Res Hum Retroviruses 22: 854-864.
21. Asada Y, Sukemori A, Watanabe T, Malla KJ, Yoshikawa T, et al. (2011) Stelleralides A-C, novel potent anti-HIV daphnane-type diterpenoids from Stellera chamaejasme L. Org Lett 13: 2904-2907.
22. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L, (1992) Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol 30: 1787-1794.
23. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS, (1987) Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238: 800-802.
24. Kehrl JH, Fauci AS, (1989) Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 86: 2365-2368.
25. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206: 1273-1289.
26. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, et al. (2005) Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virology 79: 6089-6101.
27. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, et al. (2003) Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 13: 1857-18599.
28. Márquez N, Calzado MA, Sánchez-Duffhues G, Pérez M, Minassi A, et al. (2008) Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation. Biochem Pharmacol 75: 1370-80.
29. Bedoya LM, Márquez N, Martínez N, Gutiérrez-Eisman S, Alvarez A, et al. (2009) SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro. Biochem Pharmacol 77: 965-978.
30. Mehla R, Bivalkar-Mehla S, Zhang R, Handy I, Albrecht H, et al. (2010) Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One 5: e11160.
31. Wender PA, Kee JM, Warrington JM, (2008) Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. Science 320: 649-652.
32. Rullas J, Bermejo M, García-Pérez J, Beltán M, González N, et al. (2004) Prostratin induces HIV activation and down regulates HIV receptors in peripheral blood lymphocytes. Antivir Ther 9: 545-554.
33. Newton AC, (2010) Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 298: E395-402.